NEWARK, Calif. & LONDON--(BUSINESS WIRE)--Oraya Therapeutics Inc. announced today that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone. Oraya Therapy uses low-energy, highly targeted X-rays to treat Wet AMD and is intended as a one-time procedure with the potential to maintain vision while reducing the required number of anti-VEGF injections into the eye.
Help employers find you! Check out all the jobs and post your resume.
